The global cord blood market has matured substantially over the past few years, creating both novel opportunities and serious threats.
The global cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.
Serious threats to the industry include:
- New accreditation requirements that have increased the cost structure of cord blood banks
- A decline in cord blood transplants in 2013, within the U.S. and other geographical regions
- Low rates of turnover for stored cord blood units
- Expensive cord blood transplantation procedures, costing from $200-300K each
- Difficulty with educating obstetricians about cellular therapies
- Poor press coverage in many regions worldwide, including major news outlets
Other uncontrollable factors that could threaten the industry include: new legislation, changes in transplant reimbursement, continually evolving accreditation requirements, the potential for competitive approaches to be shown as more optimal, patent challenges for processing or transplant technologies, changes in public perception of private vs. public banking, shift in policy recommendations by influential medical organizations, and changes in government support.
Marketing pressures are also impacting the industry, with the term “cord blood” becoming one of the 20 most expensive search terms on Google, reaching more than $20 per click for global search traffic and close to $40 per click for U.S. search traffic.
However, there are also emerging opportunities, including:
- The potential to expand market size through increasing public awareness
- New clinical trial data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue
- Improving public perception toward stem cell therapies
- Substantial deal-making within the industry, including mergers, acquisitions, and funding rounds
- The potential for cross-organizational collaboration through formation of Cord Blood Industry Associations (occurring in within U.S. and South America)
- A trend toward diversification within the industry, with cord blood banks effectively becoming stem cell banks through the storage of cord blood, cord tissue, and in some cases, placental tissue, amniotic fluid, and more
Within this rapidly evolving ecosystem, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
A Global Market Requires Global Understanding
While these factors vary somewhat by market, there is a substantial advantage to having a global understanding of the market. You need to understand successes and failures by region to be fully informed of your competitive environment. You need to have a firm understanding of emerging trends that could expand to new regions and impact your business model. In addition, research advances, clinical trial findings, and technology advances do not know international boundaries. They are shared nearly instantly from region-to-region.
The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
Furthermore, cord blood banks now exist in every developed country, as well as within most developing nations. With approximately 500 cord blood banks operating worldwide, maturation of the global cord blood market means that each cord blood bank is now fighting harder for market share.
Currently, the U.S. cord blood banking industry is the most mature cord blood banking market in the world, having the:
- First company to offer cord blood storage (1995)
- Largest total number of industry participants (both public and private)
- Greatest number of cord blood units (CBU) stored
- Most cord blood units banked relative to population
However, other regions have contributed major events as well.
In 2008, a Taiwanese company, HealthBanks Biotech Company Ltd. became the first company to offer cord tissue storage; it was not until July 2010 that the first private U.S. cord blood bank began offering the service (Cord Blood Registry). Since then, the trend of cord tissue storage has had a significant impact on the cord blood banking industry, with a large percentage of cord blood banks worldwide offering the service.
In China, the government shocked the cord blood industry worldwide when it announced that only one cord blood bank would be allowed to operate within each province, and official government support, authorization, and permits would be required. While the China Cord Blood Corporation has since earned permits for three of the seven Chinese provinces (holding majority share of the Chinese cord blood market) and is now competing as one of the fastest growing cord blood banks in the world, several other providers of cord blood services disappeared when this legislation was passed.
In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region.
In Ecuador, the government is now creating the first public cord blood bank and has instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This has created a crisis for the private banks, and there are now only two remaining in Ecuador.
Clearly, it is vital to understand the market dynamics and risks, as well as the emerging opportunities within different regions of the world,
Cord Blood Stem Cells, as Compared to Other Stem Cell Alternatives
Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine (1). Cord blood stem cells have distinct advantages over other sources, including that they are:
- More adaptable
- More pure
These traits result from cord blood stem cells being the earliest (non-controversial) stem cells that can be extracted from a living human, and therefore haven't been exposed to viruses, chemicals, or pollutants in the environment that can alter cell function.
While bone marrow stem cells are the most commonly recognized type of stem cell used in transplant, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant. Although cord blood banks began offering their services in the United States in the mid-1990's, it is within the past ten-years that the percentage of cord blood transplants has significantly increased.
Today, it is clear that the stem cells contained within cord blood banking have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide. However, many expectant parents still do not fully understand the significance of cord blood storage.
Awareness Levels Remain a Substantial Limitation to Market Potential
A study published in the 2006 Journal of Reproductive Medicine showed that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” The study also identified that 84% of prenatal patients expected their obstetricians to be able to provide them with information on the subject of cord blood banking; however, only about 14% were educated about cord blood banking by their nurse or obstetrician.
Unfortunately, a January 2014 Parent Survey conducted by BioInformant Worldwide, LLC (600+ responses from recent and expectant parents), identified that these percentages have shifted very little since 2006, despite attempts in most countries worldwide to encourage healthcare providers to offer prenatal patients balanced information on public and private cord blood banking options.
Key Survey Findings from 600+ Recent and Expectant Parents
In addition to exploring awareness rates, this 40-question, 52-page survey explores topics that include how to strategically position your products, effectively educate parents, prioritize your marketing budget, and understand why parents bank publicly, privately, or not at all.
It also reveals the most popular blogs, websites, and apps among expectant parents, and it provides key insight into the minds of your prospective clients. Use the findings from this section to make effective decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
With responses from 600+ recent and expectant parents worldwide, this comprehensive survey will substantially improve your ability to position cord blood banking services.
Key survey findings include:
- Rates of cord blood banking awareness by gender, income, geographic location, and education
- Sources through which expectant parents learn of cord blood preservation
- Factors influencing private vs. public storage of cord blood
- Price sensitivity and quality expectations
- Approaches for communicating with expectant parents
- Key factors influencing the decision to store cord blood
- Parental responsiveness to health statistics
- “Tested" language for communicating with expectant parents
- And more
Key Report Findings
The report is designed to guide the decision-making of cord blood banks worldwide, as well as to advise private, corporate, and institutional investors entering into this market.
As such, it considers a range of metrics that impact the global cord blood banking market. It includes trend rate data for cord blood clinical trials, patents, grants, scientific publications and more. For instance, there are now more than 500 studies involving cord blood listed on ClinicalTrials.gov, and there have been hundreds of patents related to cord blood collection, processing, and storage filed through the United States Patent and Trademark Office. Globally, this patent count is even larger.
Additionally, the year-over-year increase in scientific publications on PubMed.gov containing the term “cord blood” increased by 7.8% from 2013 to 2014. PubMed.gov is a global database of scientific publications containing more than 24 million citations for biomedical literature, which makes it an excellent resource for gauging biomedical research trends. However, grant rate data reveals that funding for cord blood related research has been declining from 2012 to present.
Key report findings include:
- Market size determinations for the global cord blood market
- Trend rate data for umbilical cord blood grants, patents, and scientific publications
- Clinical trial rate analysis, including comparison of cord blood vs. cord tissue frequency
- Rates of global cord blood storage (units per year)
- Rates of global cord blood transplant (units per year)
- Current and future conditions treatable with cord blood
- Probability of requiring a stem cell transplant by age
- Trends in medical opinions of cord blood banking
- Changes in legislative support for cord blood banking
- Critical events and emerging technologies within the cord blood industry
- Competitive environment analysis, including assessment of cord blood market leaders
- Influential alliances within the cord blood industry
- "SWOT" analysis for global cord blood industry (Strengths, Weaknesses, Opportunities, Threats)
- Crucial trends and unmet market needs
- And much more
This report also features an extensive Appendix that includes "Existing Conditions Treatable with Cord Blood Transplant," a "Global List of Cord Blood Banks," "AABB Accredited Cord Blood Banks Worldwide," and more.
This global strategic report is based on BioInformant's real-time monitoring of the global cord blood marketplace, including cord blood databases that have been continuously updated for nearly a decade.
It presents data sourced from global public databases, including scientific publication databases, clinical trial databases, grant funding databases, patents databases, cord blood storage registries, cord blood transplant registries, Google Adwords (search term analysis), Google News (industry announcements), and more.
It also presents publicly stated revenue figures for cord blood banks worldwide.
Importantly, it presents metrics and findings from the World Cord Blood Congress 2014, the largest commercial cord blood banking and therapy conference in North America that brings together stakeholders from across the cord blood market. Our team attended this event September 16-17, 2014, in Boston, MA, USA.
All sources are verifiable by third-party analysis.
A key element that sets BioInformant apart is that our leadership team comes from a "Bioinformatics" background - the science of collecting and analyzing complex genetic codes. We're trained in applying these advanced research techniques to the field of stem cell market research.
BioInformant employs advanced techniques for deriving unique stem cell market research. The following constitute the basis for our Research & Analysis:
- Preliminary Research: Extensive secondary research based on preliminary market evaluations.
- Fill-Gap Research: Selectively sampled and focused primary research as a fill-gap strategy.
- Historic Analysis - Primary Products: Comprehensive analysis of all data for each primary product market.
- Historic Analysis - End-user Markets: Historic analysis of all end-user industries/markets, requiring technology and market evaluations, growth projections, and market size estimation of end-user markets.
- Historic Supply Chain/Raw Materials Analysis: Comprehensive analysis of data for each primary market segment.
- Data Consolidation: Merging historic end-user market data to yield consolidated primary market data.
- Cross Linking: Comparing primary market data (historic) with resulting end-user consolidated market data and calculating the variance in percentages between data sets by year.
- Variance Determination: Placing a median figure for each year with a tolerance range equal to twice the variance percentage and recording the resulting numbers.
- Projections: Projecting forward end-user markets based upon historic metrics, technology and market trends, and primary research from the marketplace.
- Variance Factorization: Consolidation of projected end-user market data to yield derived primary market data. The data is adjusted to the historic variance determinations, as above. The resulting data is verified by confirmatory primary research.
- Confirmatory Primary Research: Presenting resulting data from companies or individuals participating as research partners. Variations from derived data are adjusted to reflect primary research based consensus.
- Electronically Based End-User Surveys: Distribution of electronically based end-user surveys to a panel of industry representatives working within market segment(s) of interest. Statistical analysis is performed on collected user-response data.
Table of Contents
II. Overview of Technical & Medical Characteristics of Cord Blood
- A. Introduction to Cord Blood and Cord Tissue
- B. Definitions and Nomenclature
- C. Technical Advantages of Cord Blood
- (Image) TECHNICAL ADVANTAGES OF CORD BLOOD TRANSPLANT, OVER BONE MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANT
- D. Likelihood of Needing a Stem Cell Transplant
- 1. Childhood Probability
- (Table) CHILDHOOD PROBABILITY OF REQUIRING A STEM CELL TRANSPLANT
- 2. Adulthood Probability
- (Table) ADULTHOOD PROBABILITY OF REQUIRING A STEM CELL TRANSPLANT
- (Chart) LIKELIHOOD OF REQUIRING A STEM CELL TRANSPLANT (FROM CORD BLOOD, BONE MARROW, OR PERIPHERAL BLOOD)
- E. Comparison of Cord Blood, Bone Marrow, and Peripheral Blood Stem Cell Transplant
- (Image) GROUNDBREAKING YEARS IN TRANSPLANT HISTORY
- F. Conditions Treatable with Cord Blood Transplant
- (Image) CORD BLOOD TREATMENT OPTIONS: NOW & IN THE FUTURE
- (Table) DISEASE CATEGORIES TREATABLE WITH HEMATOPOIETIC STEM CELL TRANSPLANT
- (Table) FUTURE DISEASE CATEGORIES TREATABLE WITH CORD BLOOD TRANSPLANT
III. Cord Blood Market Overview
- A. Market Variation
- B. Cord Blood Banking Structures
- (Table) FREE CORD BLOOD PROGRAM FOR FAMILIES IN NEED IN THE UNITED STATES
- C. Accreditation Standards and Requirements
- 1. Types of Accreditation
- 2. AABB Accreditation
- (Table) COUNTRIES CONTAINING AABB ACCREDITED CORD BLOOD BANKS
- (Chart) COUNTRIES WITH AABB ACCREDITED CORD BLOOD FACILITIES
IV. Cord Tissue Market Overview
- A. History of Cord Tissue Storage
- B. Comparison of Cord Blood & Cord Tissue Storage
- (Image) COMPARISON OF UMBILICAL CORD BLOOD VS. UMBILICAL CORD TISSUE
- C. Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
- (Table) MEDICAL CONDITIONS BEING INVESTIGATED FOR POTENTIAL TO BE TREATED WITH CORD TISSUE DERIVED MESENCHYMAL STEM CELL (CT-MSCs)
- (Image) SOURCES OF MESENCHYMAL STEM CELLS
- D. Market Penetration of Cord Tissue within the U.S
- (Table) U.S. CORD BLOOD BANKS OFFERING CORD TISSUE STORAGE IN 2013
- (Table) U.S. CORD BLOOD BANKS OFFERING CORD TISSUE STORAGE IN 2015
- E. Pricing of Cord Tissue Storage (Global Analysis)
- (Table) PRICING STRUCTURES FOR CORD TISSUE STORAGE
V. Timeline of Key Cord Blood Industry Events
VI. Key Processing Technologies within Cord Blood Marketplace
- (Image) THE FOUR KEY PROCESSING TECHNOLOGIES OPERATING WITHIN THE CORD BLOOD BANKING MARKET
- A. AutoXpress® Platform (“AXP®”) and BioArchive System (By Thermogenesis, a Division of Cesca Therapeutics in Rancho Cordova, California, USA)
- B. Sepax (By Biosafe, in Eysins, Switzerland)
- C. PrepaCyte®-CB (By BioE in St. Paul, Minnesota, USA)
- D. Cord Blood 2.0TM (By Americord, in New York, NY, USA)
VII. Strategic Collaborations: Key Alliances within Cord Blood Industry
- A. Cord Blood Registry and Women's Health Alliance (Largest Women's Healthcare Groups)
- B. ViaCord and Destination Maternity (Largest Retailer of Maternity Clothing)
- C. Precious Cells Miracle and the Croydon Health Services NHS Trust
- D. CarePilot and “Cord for Life” (Lifeforce Cryobank's Cord Blood Storage Program)
- E. Cesca Therapeutics and UpState Public Cord Blood Bank
VIII. Cord Blood Industry Trend: Diversification into Stem Cell Bio-Banking
- A. Overview
- (Table) TYPES OF STEM CELL BIO-BANKING
- B. Dental Stem Cell Storage
- (Table) COMPANIES OFFERING DENTAL STEM CELL STORAGE (BOTH DIVERSIFIED CORD BLOOD BANKS AND SPECIALTY COMPANIES)
- C. Adipose-Derived Stem Cell Storage
- (Table) COMPANIES OFFERING ADIPOSE-DERIVED STORAGE (BOTH DIVERSIFIED CORD BLOOD BANKS AND SPECIALTY COMPANIES)
- D. Other Types of Stem Cell Bio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More
IX. Comparative Analysis of Cord Blood Market Leaders
- A. Largest Cord Blood Banks, by Units Banked
- 1. Top 3 U.S. Cord Blood Banks
- a. Cord Blood Registry (Acquired by AMAG Pharmaceuticals)
- b. ViaCord
- c. Cryo-Cell International
- d. Comparative Analysis of Top 3 U.S. Cord Blood Banks
- (Table) COMPARATIVE ANALYSIS OF SERVICES & FEATURES (U.S.)
- (Table) COMPARATIVE ANALYSIS OF PRICING (U.S.)
- 2. Top 3 Global Cord Blood Banks
- a. Cryo-Save
- b. CordVida
- c. China Cord Blood Corporation
- d. Comparative Analysis of Top 3 Global Cord Blood Banks
- (Table) COMPARATIVE ANALYSIS OF SERVICES & FEATURES (Worldwide)
- B. Fastest Growing Cord Blood Banks, by Revenue
- 1. U.S. Analysis
- 2. International Analysis
- (Chart) China Cord Blood Corporation Compounded Annual Growth Rates (CAGR), FY2009-FY2014
- (Chart) China Cord Blood Corporation's Public Division Compounded Annual Growth Rates (CAGR), FY2009-FY2014
X. “SWOT” Analysis for Cord Blood Marketplace
- A. Strengths
- (Table) STRENGTHS OF THE GLOBAL CORD BLOOD BANKING MARKET
- B. Weaknesses
- (Table) WEAKNESSES OF THE GLOBAL CORD BLOOD BANKING MARKET
- C. Opportunities
- (Table) OPPORTUNITIES WITHIN THE GLOBAL CORD BLOOD BANKING MARKET
- D. Threats
- (Table) THREATS TO THE GLOBAL CORD BLOOD BANKING MARKET
XI. Trend Rate Analysis
- A. Scientific Publication Rate Analysis
- (Table) TREND RATE ANALYSIS OF SCIENTIFIC PUBLICATION RATES, BY YEAR
- (Chart) ANALYSIS OF SCIENTIFIC PUBLICATIONS CONTAINING “CORD BLOOD” (SOURCE: PUBMED)
- (Chart) FIVE-YEAR FUTURE PROJECTION ANALYSIS OF SCIENTIFIC PUBLICATIONS CONTAINING “CORD BLOOD” (SOURCE: PUBMED)
- (Chart) ANALYSIS OF SCIENTIFIC PUBLICATIONS CONTAINING “CORD TISSUE” (SOURCE: PUBMED)
- (Chart) FIVE-YEAR FUTURE PROJECTION ANALYSIS OF SCIENTIFIC PUBLICATIONS CONTAINING “CORD TISSUE” (SOURCE: PUBMED)
- B. Grant Funding Analysis
- (Table) TREND RATE ANALYSIS OF CORD BLOOD GRANTS, BY YEAR (RePORTER Tool)
- (Chart) ANALYSIS OF RESEARCH GRANTS CONTAINING “CORD BLOOD” (SOURCE: RePORTER TOOL BY NATIONAL INSTITUTES OF HEALTH)
- (Image) DENSITY OF RESEARCH GRANTS IN THE U.S. CONTAINING “CORD BLOOD” IN DESCRIPTION
- (Image) EUROPEAN SITES OF ORGANIZATIONS THAT HAVE FUNDED PROJECTS CONTAINING “CORD BLOOD” IN DESCRIPTION
- (Image) WORLDWIDE SITES OF ORGANIZATIONS THAT HAVE FUNDED PROJECTS CONTAINING “CORD BLOOD” IN DESCRIPTION
- C. Patent Analysis
- (Table) PATENTS CONTAINING THE WORD “CORD BLOOD” IN THE TITLE (USPTO.GOV)
- (Table) CATEGORICAL BREAKDOWN OF U.S. PATENTS WITH “CORD BLOOD” IN TITLE
- (Chart) CATEGORICAL BREAKDOWN OF U.S. PATENTS WITH “CORD BLOOD” IN TITLE
- D. Clinical Trial Rate Analysis
- 1. Quantitative Analysis (Year-by-Year)
- (Table) CLINICAL TRIALS WITH “CORD BLOOD” IN THE DESCRIPTION (CLINICALTRIALS.GOV)
- (Chart) NUMBER OF CLINICAL TRIALS WITH “CORD BLOOD” IN THE DESCRIPTION
- 2. Geographic Analysis
- (Table) GEOGRAPHICAL BREAKDOWN OF CLINICAL STUDIES WITH “CORD BLOOD” IN DESCRIPTION (CLINICALTRIALS.GOV)
- (Image) GEOGRAPHICAL BREAKDOWN OF CLINICAL STUDIES WITH “CORD BLOOD” IN DESCRIPTION (CLINICALTRIALS.GOV)
- E. Market Penetration Rate of Cord Blood Storage
XII. Cord Blood Marketing Analysis: Search Terms “Cord Blood” and “Cord Tissue”
- (Image) GOOGLE ADWORDS PRICE-PER-CLICK FOR TERM “CORD BLOOD” (GEOGRAPHY: USA ONLY)
- (Image) GOOGLE ADWORDS PRICE-PER-CLICK FOR TERM “CORD BLOOD” (GEOGRAPHY: WORLDWIDE)
- (Image) SEARCH TERMS CONTAINING THE PHRASE “CORD BLOOD” WITHIN THEM (GEOGRAPHY: USA ONLY)
- (Image) SEARCH TERMS CONTAINING THE PHRASE “CORD BLOOD” WITHIN THEM (GEOGRAPHY: WORLDWIDE)
- (Table) GOOGLE ADWORDS PAY-PER-CLICK PRICES FOR CORD BLOOD RELATED SEARCH TERMS
XIII. Key Cord Blood Industry Benchmarks
- A. Medical Society Opinions of Cord Blood Banking
- (Table) CORD BLOOD BANKING OPINIONS ISSUED BY MEDICAL SOCIETIES
- B. Rates of Parental Awareness
- (Image) LACK OF AWARENESS A MAJOR PROBLEM FOR CORD BLOOD PRESERVATION
- C. Rates of Worldwide Storage, by Year
- (Table) CORD BLOOD BANKING UNITS IN THE BONE MARROW DONORS WORLDWIDE DATABASE
- (Chart) NUMBER OF CORD BLOOD UNITS IN THE BMDW CORD BLOOD REGISTRY, BY YEAR
- (Chart) TOTAL NUMBER OF CORD BLOOD UNITS IN THE BMDW CORD BLOOD REGISTRY, JUNE - NOVEMBER 2014
- D. Transplant Data
- (Image) # OF CORD BLOOD TRANSPLANTS, BY YEAR (BMDW)
- E. Quality Guarantee Comparison
- (Table) COMPARISON OF LEADING PRIVATE CORD BLOOD BANKS IN THE USA (RANKED BY VALUE OF "QUALITY GUARANTEE")
XIV. Market Size Analysis
- A. Definitions
- B. Methodology
- (Chart) PERCENT OF GLOBAL CORD BLOOD BANKING MARKET, BY SEGMENT
- C. Market Size Estimations
- (Table) REVENUE ESTIMATIONS BY MARKET SEGMENT
XV. Global Analysis of Cord Blood Market Authorities
- A. People: Top Five Cord Blood Influencers
- 1. Dr. Elaine Gluckman; Performed the First Related Cord Blood Transplant
- 2. Dr. Joanne Kurtzberg; Performed First Unrelated Cord Blood Transplant
- 3. Dr. Pablo Rubinstein; Co-founder & Director of the National Cord Blood Program in the New York Blood Center
- 4. Dr. Hal Broxmeyer; First to Suggest Cord Blood as a Source of Hematopoietic Stem Cells
- 5. Jeffrey Crouse; CEO of Cord Blood Registry
- B. Cord Blood Banks: Top Ten Most Influential Cord Blood Banks Worldwide
- 1. Cord Blood Registry (San Bruno, California, USA)
- 2. ViaCord (Waltham, Massachusetts, USA)
- 3. CryoCell (Oldsmar, Florida, USA)
- 4. China Cord Blood Corporation (Daxing, Beijing, China)
- 5. Cryo-Save (Zutphen, Netherlands)
- 6. New York Cord Blood Program (New York City, New York, USA)
- 7. CordVida: (São Paulo, Brazil)
- 8. Americord (New York City, New York, USA)
- 9. Cord Blood America (Las Vegas, Nevada, USA)
- 10. Crioestaminal (BioCant Park, Portugal)
- C. Events: Global Cord Blood Conferences & Events
- (Table) GLOBAL CORD BLOOD CONFERENCES & EVENTS
- D. Investors & Acquisitions Impacting the Cord Blood Market
- 1. ABS Capital Partners & HLM Management
- 2. KKR & Company
- 3. Bay City Capital
- 4. GTCR, LLC
- 5. Related Industry Investments
XVI. INVESTORS AND ACQUISITIONS IMPACTING THE CORD BLOOD MARKET
- (Table) INDUSTRY INVESTORS WITHIN CORD BLOOD MARKET
- (Table) MAJOR ACQUISITIONS WITHIN CORD BLOOD MARKET
- A. Investors Impacting the Global Cord Blood Market
- 1. ABS Capital Partners & HLM Management
- 2. KKR & Company
- 3. Bay City Capital
- 4. GTCR, LLC
- 5. Excalibur (Private Equity Firm) and Christopher Evans (Biotech Entrepreneur)
- B. Acquisitions Impacting the Global Cord Blood Market
- 1. Summary of Acquisitions
- 2. Strange Similarities between Acquisition of Cord Blood Registry and ViaCord
- a. Sample Multiple on Revenue
- b. Same Location of Acquiring Company
- c. Two Largest Cord Blood Banks within the United States
- (Table) COMPARISON OF ACQUISITION OF CORD BLOOD REGISTRY BY AMAG PHARMACEUTICALS AND VIACORD BY PERKINELMER
XVII. Cord Blood Industry Analysis: Geographic Regions with Shifting Conditions
- A. China
- B. France and Italy
- C. Taiwan
- D. Ecuador
- E. South Africa
- F. Brazil
XVIII. Cord Blood Banking Survey: 600+ Recent & Expectant Parents (Geography: Worldwide)
- A. Overview of Survey Design
- B. Population Characteristics of Respondents (Questions 1 - 7; All Respondents)
- C. Survey Results: Respondents who Banked Privately (Questions 8 - 25; 61 Respondents)
- D. Survey Results: Respondents who Banked Publicly (Questions 26 - 29; 154 Respondents)
- E. Survey Results: Respondents who Did Not Bank (Question 30 - 33; 377 Respondents)
- F. General Findings (Questions 34 - 40; All Respondents)
XIX. Summary of Conclusions
- APPENDIX A - Existing Conditions Treatable with Hematopoietic Stem Cell Transplant
- APPENDIX B - AABB Accredited Cord Blood Banks Worldwide
- APPENDIX C - List of U.S. Cord Blood Banks, by Type of Bank (Private, Hybrid, or Public)
- APPENDIX D - Global List of All Active Cord Blood Banks Worldwide